Expert view: Tackling drug discovery inefficiencies requires diverse libraries, technologies with broader applicability and actionable insights
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.